ASKA Pharmaceutical Holdings Co Ltd
TSE:4886
Income Statement
Earnings Waterfall
ASKA Pharmaceutical Holdings Co Ltd
Revenue
|
62B
JPY
|
Cost of Revenue
|
-32.2B
JPY
|
Gross Profit
|
29.9B
JPY
|
Operating Expenses
|
-24.3B
JPY
|
Operating Income
|
5.6B
JPY
|
Other Expenses
|
920m
JPY
|
Net Income
|
6.5B
JPY
|
Income Statement
ASKA Pharmaceutical Holdings Co Ltd
Sep-2020 | Dec-2020 | Mar-2021 | Jun-2021 | Sep-2021 | Dec-2021 | Mar-2022 | Jun-2022 | Sep-2022 | Dec-2022 | Mar-2023 | Jun-2023 | Sep-2023 | Dec-2023 | ||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Revenue | |||||||||||||||
Revenue |
53 363
N/A
|
54 685
+2%
|
55 181
+1%
|
55 688
+1%
|
56 255
+1%
|
56 010
0%
|
56 607
+1%
|
57 655
+2%
|
58 302
+1%
|
59 687
+2%
|
60 461
+1%
|
61 215
+1%
|
61 937
+1%
|
62 026
+0%
|
|
Gross Profit | |||||||||||||||
Cost of Revenue |
(28 596)
|
(28 905)
|
(29 798)
|
(29 689)
|
(30 286)
|
(30 260)
|
(30 255)
|
(30 741)
|
(31 074)
|
(31 663)
|
(31 876)
|
(32 418)
|
(32 467)
|
(32 176)
|
|
Gross Profit |
24 767
N/A
|
25 780
+4%
|
25 383
-2%
|
25 999
+2%
|
25 969
0%
|
25 750
-1%
|
26 352
+2%
|
26 914
+2%
|
27 228
+1%
|
28 024
+3%
|
28 585
+2%
|
28 797
+1%
|
29 470
+2%
|
29 850
+1%
|
|
Operating Income | |||||||||||||||
Operating Expenses |
(22 921)
|
(22 747)
|
(21 774)
|
(22 108)
|
(21 649)
|
(21 240)
|
(21 557)
|
(29 785)
|
(23 471)
|
(22 641)
|
(23 477)
|
(23 649)
|
(24 186)
|
(24 257)
|
|
Selling, General & Administrative |
(22 060)
|
(22 016)
|
(21 773)
|
(22 099)
|
(21 647)
|
(21 240)
|
(17 958)
|
(21 642)
|
(22 210)
|
(22 863)
|
(19 249)
|
(23 648)
|
(24 184)
|
(24 256)
|
|
Research & Development |
0
|
0
|
0
|
0
|
0
|
0
|
(3 598)
|
0
|
0
|
0
|
(4 227)
|
0
|
0
|
0
|
|
Other Operating Expenses |
(861)
|
(731)
|
(1)
|
(9)
|
0
|
0
|
(1)
|
(8 143)
|
(1 261)
|
222
|
(1)
|
(1)
|
(2)
|
(1)
|
|
Operating Income |
1 846
N/A
|
3 033
+64%
|
3 609
+19%
|
3 891
+8%
|
4 320
+11%
|
4 510
+4%
|
4 795
+6%
|
(2 871)
N/A
|
3 757
N/A
|
5 383
+43%
|
5 108
-5%
|
5 148
+1%
|
5 284
+3%
|
5 593
+6%
|
|
Pre-Tax Income | |||||||||||||||
Interest Income Expense |
172
|
177
|
216
|
738
|
725
|
690
|
202
|
166
|
235
|
408
|
369
|
456
|
2 659
|
3 137
|
|
Non-Reccuring Items |
0
|
0
|
(8)
|
0
|
(6 890)
|
(8 374)
|
(8 142)
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
Gain/Loss on Disposition of Assets |
0
|
0
|
0
|
0
|
0
|
9 425
|
9 382
|
0
|
0
|
0
|
(52)
|
0
|
0
|
0
|
|
Total Other Income |
(83)
|
(730)
|
(242)
|
(712)
|
(671)
|
(54)
|
(74)
|
9 344
|
9 329
|
(110)
|
(68)
|
(179)
|
(195)
|
(220)
|
|
Pre-Tax Income |
1 935
N/A
|
2 480
+28%
|
3 575
+44%
|
3 917
+10%
|
(2 516)
N/A
|
6 197
N/A
|
6 163
-1%
|
6 639
+8%
|
13 321
+101%
|
5 681
-57%
|
5 357
-6%
|
5 425
+1%
|
7 748
+43%
|
8 510
+10%
|
|
Net Income | |||||||||||||||
Tax Provision |
(311)
|
(445)
|
(861)
|
(843)
|
881
|
(1 851)
|
(1 873)
|
(2 125)
|
(3 888)
|
(1 291)
|
(1 118)
|
(1 080)
|
(1 725)
|
(1 996)
|
|
Income from Continuing Operations |
1 624
|
2 035
|
2 714
|
3 074
|
(1 635)
|
4 346
|
4 290
|
4 514
|
9 433
|
4 390
|
4 239
|
4 345
|
6 023
|
6 514
|
|
Net Income (Common) |
1 624
N/A
|
2 036
+25%
|
2 713
+33%
|
3 072
+13%
|
(1 635)
N/A
|
4 344
N/A
|
4 290
-1%
|
4 515
+5%
|
9 432
+109%
|
4 391
-53%
|
4 238
-3%
|
4 343
+2%
|
6 021
+39%
|
6 513
+8%
|
|
EPS (Diluted) |
57.28
N/A
|
71.81
+25%
|
95.69
+33%
|
108.25
+13%
|
-57.56
N/A
|
152.89
N/A
|
151.22
-1%
|
160.18
+6%
|
334.07
+109%
|
155.37
-53%
|
150.08
-3%
|
153.53
+2%
|
212.66
+39%
|
229.93
+8%
|